Clinical Trial Delay and Staff Cuts Trigger Sharp Decline for Bolt Biotherapeutics

Shares of Bolt Biotherapeutics are trading significantly lower following a dual announcement of a major clinical program delay and a substantial workforce reduction. The company revealed that pivotal data for its flagship asset, BDC-4182, will arrive later than anticipated, concurrently disclosing plans to cut its employee base by half to preserve capital. This news precipitated a steep sell-off, erasing more than 16 percent of the stock’s value within a 48-hour period.

In a decisive move to manage its resources, Bolt Biotherapeutics is implementing a restructuring plan that will reduce its team size by 50%. Management states this difficult action is necessary to extend the company’s financial liquidity into 2027. CEO Willie Quinn attributed the decision to “challenging market conditions,” emphasizing the “strategic... Read more...